Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States …
$7.77-3.84%
报价 2026-11-13
市值
$401.7M
EV
$316.9M
PE (TTM)
10.1x
预期 PE (FY2026)
20.4x
52 周区间距高点 -31.0%
$4.84$11.26
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PBYIPuma Biotechnology, Inc. | $401.7M | -3.8% | +2.0% | 74.5% | 10.1x | 5.4x | 27.8x | |
| AVIRAtea Pharmaceuticals, Inc. | $345.3M | +2.1% | -19.7% | 0% | – | – | – | |
| SGMTSagimet Biosciences Inc. | $333M | -6.5% | -90.0% | 0% | – | – | – | |
| ALLOAllogene Therapeutics, Inc. | $290.6M | +1.4% | +1.3% | 0% | – | – | – | |
| ARCTArcturus Therapeutics Holdings Inc. | $241M | -0.9% | -81.3% | 24% | – | – | – | |
| TRDAEntrada Therapeutics, Inc. | $199.3M | -1.5% | -36.1% | 57.5% | – | – | – | |
| ELDNEledon Pharmaceuticals, Inc. | $178.6M | -10.6% | -100.0% | 0% | – | – | – | |
| HUMAHumacyte, Inc. | $155.1M | -6.2% | +174.1% | -533% | – | – | – | |
| ABEOAbeona Therapeutics Inc. | $138.3M | +5.7% | +1241.7% | 26.3% | 3.3x | – | – | |
| 同行中位数 | – | – | -27.9% | 0% | 3.3x | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。
研究材料
电话会纪要摘要
暂无纪要摘要。